In clinical situations, JAK2 amplification in tumor samples is strongly associated with poor recurrence-free survival, poor overall survival, and low responsiveness to neoadjuvant chemotherapy in breast cancer patients [37,38]. This evidence concerns the gene JAK2 and breast carcinoma.